Moderna’s stunning surge and drop, AI in scientific writing, and more biotech news from The Readout Adobe Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Cancer patients may be receiving higher doses and longer courses of expensive drugs than they need. Also, we see Moderna’s stock swing some thanks to profit-taking, and… … I’ve taken to channeling Diogenes these days, choosing lentils over tyranny. I recommend, they’re most fibrous. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.
STAT+: Are cancer patients getting too much drug?
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.